SLC7A11 and glioma: PRMT1 promotes ferroptosis by suppressing key antioxidant systems, including solute carrier family 7-member 11 (SLC7A11), and its inhibition could provide dual therapeutic benefits—enhancing neuroprotection while improving treatment responses in conditions like gliomas (Li et al., 2024d).